SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer): a partially double-blinded, multi-center, randomized, controlled superiority study-
Providence: Prospective non-interventional study (NIS) to examine patient-reported outcomes and real-world clinical data in patients with HER2-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer treated with Trastuzumab Deruxtecan
HIGHLIGHT 1: Eine randomisierte, placebokontrollierte, doppelblinde klinische Studie der Phase III zur Untersuchung der Wirksamkeit und Sicherheit von Fezolinetant für die Behandlung mittlerer bis schwerer vasomotorischer Symptome (Hitzewallungen) bei Frauen mit Hormonrezeptor-positivem Brustkrebs im Stadium 0 bis 3, die eine adjuvante endokrine Therapie erhalten
BCP: Breast Cancer in Pregnancy Register Study
HerediCaRe: Register zur Langzeit-Dokumentation von genetischen und klinischen Daten aus der Routineversorgung von Familien mit einer erblichen Belastung für Brust- und Eierstockkrebs
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
LOBSTER: Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer
DYNASTY-Breast02: A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET)
FLAMINGO-01: A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy
Ember-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
ADAPT TN 3: NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab in low-risk, triple-negative early breast cancer
Caroleen: A non-interventional study for Kisqali (ribociclib) in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer at high risk of recurrence to evaluate real-world effectiveness, safety profile, patient compliance and quality of life
Elegant: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study
Element: Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-ofcare olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations
BMBC (Brain Metastases in Breast Cancer Network Germany): Registerstudie für prospektiv und retrospektiv Daten zu Erkrankungsverläufen von Patientinnen mit Hirnmetastasen eines Mammakarzinoms
